Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Neuraxis (NRXS) EBIT (2022 - 2025)

Neuraxis' EBIT history spans 4 years, with the latest figure at -$1.7 million for Q4 2025.

  • On a quarterly basis, EBIT fell 17.07% to -$1.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$7.8 million, a 9.4% decrease, with the full-year FY2025 number at -$7.8 million, down 9.4% from a year prior.
  • EBIT hit -$1.7 million in Q4 2025 for Neuraxis, up from -$2.1 million in the prior quarter.
  • Over the last five years, EBIT for NRXS hit a ceiling of -$669582.0 in Q2 2022 and a floor of -$3.0 million in Q3 2023.
  • Historically, EBIT has averaged -$1.6 million across 4 years, with a median of -$1.7 million in 2024.
  • Biggest five-year swings in EBIT: plummeted 151.21% in 2023 and later soared 45.36% in 2024.
  • Tracing NRXS's EBIT over 4 years: stood at -$986226.0 in 2022, then tumbled by 64.59% to -$1.6 million in 2023, then grew by 9.65% to -$1.5 million in 2024, then fell by 17.07% to -$1.7 million in 2025.
  • Business Quant data shows EBIT for NRXS at -$1.7 million in Q4 2025, -$2.1 million in Q3 2025, and -$1.7 million in Q2 2025.